

**Name** Jørgen Ingerslev

**Nationality** Danish

**Present Position**

MD, DMSc

Professor emeritus in Haemostasis and Thrombosis at Aarhus University

**Education**

1968 Århus University Gold Medal Award, Clinical Biochemistry

1970 MD, University of Aarhus

1970 US Medical Examination (EFCMG)

1980 National Board Autorization, Internal Medicine

1981 National Board Authorization, Clinical Biochemistry

1990 Dissertation, University of Aarhus, Faculty of Health Sciences  
"Von Willebrand Factor, Factor VIII and the Factor VIII/von  
Willebrand Factor Complex".

**Academic Positions**

1966-1968 Instructor, Medical Biochemistry, Institute for Medical  
Biochemistry, University of Aarhus

1971-73 External lecturer, internal medicine, University of Aarhus

1977-79 External lecturer, Clinical Chemistry, Univeristy of Aarhus

1979-1980 External lecturer, internal medicine, University of Aarhus

1985-1993 External lecturer, Clinical Chemistry, University of Aarhus

1993 - 1994 Senior lecturer, Clinical Biochemistry, University of Aarhus

1994-2005 Associate Professor, Clinical Biochemistry (Haemostasiology),  
University of Aarhus

2005-2010 Professor in Haemostasis and Thrombosis, University of Aarhus

2009 - 2013 Visiting Professor at King's College Medical School, London, UK

2010 – now Professor Emeritus in Haemostasis and Thrombosis, Aarhus University and Centre for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Skejby University Hospital, Aarhus, Denmark since July 2010.

#### Mentorships

In total, mentorship has been offered to 25 younger researchers in the field of thrombosis and haemostasis, including 15 PhD students.

#### **Professional goals achieved**

1992-2009 Establishment, development and maintenance of a National Comprehensive Haemophilia Care Center at Skejby Hospital. Background population covered: 2.9 Mio. inhabitants

1994-2009 Establishment, development and maintenance of a regional Diagnostic Thrombosis Reference Centre at Skejby Hospital. Background population covered:  $\cong$  1.6 Mio. inhabitants

2007- 2010 Participant in the organizing committee and subsequently Executive Committee Secretary for the newly formed European Association for Haemophilia and Allied Disorders (EAHAD)

#### **Publications**

The list of published papers today amounts to 265 reviewed articles. Amongst these 235 appeared in journals with a peer review system; 30 are review articles and book chapters.

#### **International oral presentations and abstracts**

In total > 150 oral presentations have been given at International Congresses and other meetings. >200 abstracts have been presented at International Congresses

#### ***Peer reviewing***

Peer reviewing on a regular basis for 20 Journals in areas of Haemostasis and Thrombosis and related topics

#### ***Editorial Boards***

Associate Editor Haemophilia-Forum (Web-site), 1996- 2009.

Editorial Board Member, Haemophilia 1998- 2010

Review Editor, International Monitor on Haemophilia 1992-

Editorial Board Member, Thrombosis Research 1993-2001

## Recent publications

2010:

1. Salute Trachymiene S, Ingerslev J, Rageline L. Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania. *Haemophilia* 2010; 16: 479-86
2. Larsen OH, DEzban M, Persso E, Ingerslev J, Sørensen B. Artificial contact activation masks the haemostatis potential of rFVIIa and NN1731 in thrombocytopenic whole blood. *Br J Haematol* 2010; 150: 124-7.
3. Sørensen B, Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor – clinical outcome and laboratory observations. *Thromb Haemost* 2010; 103: 1275-6.
4. Sørensen B, Fenger-Eriksen C, Christiansen K, Larsen OH, Ingerslev J. Evaluation of coagulation kinetics using thrombelastometry – methodologic influence of activator and test medium. *Ann Hematol.* 2010; 89: 1155-61.
5. Beyer R, Ingerslev J, Sørensen B. Muscle bleeds in professional athletes— diagnosis, classification, treatment and potential impact in patients with haemophilia. *Haemophilia* 2010; 16: 858-65.
6. Beyer R, Ingerslev J, Sørensen B. Current practice in management of muscle haematomas in patients with severe haemophilia. *Haemophilia* 2010; 16: 926-331.
7. Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, Shima M, St-Louis J, L'évesque H. Concensus recommendations for the diagnosis and treatment of acquired Haemophilia A. *BMC Res Notes* 2010; 3: 161.
8. Fenger-Eriksen C, Moore GW, Rangarajan S, Ingerslev J, Sørensen B. Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid expanders. *GTransfusion* 2010; 50: 2571-6.
9. Castaman G, Tosetto A, Capellatti A, Goodeve A, Federici AB, Battle J, Meyer D, Goudemand J, Eikenboom JC, Schneppenmehim R, Budde U, Ingerslev J, Lethagen S, Hill F,, Peake IR, Rodeghiero F.. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. *Thromb Res* 2010; 126: 227-31.

2011:

10. Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Battle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake IR, Rodeghiero F. The impact of bleeding history, von Willebrand factor and PFA-100 on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD
11. Rea CJ, Foley JH, Ingerslev J, Sørensen B. Factor XIII combined with recombinant factor VIIa: a new means of treating severe haemophilia A. *J Tromb Haemost* 2011; 9:510-6.
12. Mariani G, Dolce A, Batarova A, Auerswald G, Schved JF, Siragusa S, Napolitano M, Knudsen JB, Ingerslev J; STER and the International Factor VII Deficiency Study Groups. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation – the surgical STER. *Br J Haematol* 2011; 152: 340-6.
13. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Battle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake IR. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. *Haemophilia* 2011; 17: 165-6.
14. Chitlur M, Sørensen B, Rivard GE, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escobar M, Lusher J. Standardisation of thrombelastography: a report from the TEG-ROTEM working group. *Haemophilia* 2011; 17: 532-7.
15. Moessner BK, Andersen ES, Weis N, Laursen AL, Ingerslev J, Lethagen S, Pedersen C, Christensen PB. Previously unrecognised advanced liver disease unveiled by transient elastography in patients with Haemophilia and chronic hepatitis C. *Haemophilia* 2011;17: 983-43.
16. Larsen OH, Fenger-Eriksen C, Christiansen K, Ingerslev J, Sørensen B. Diagnostic performance and therapeutic consequences of thrombelastometry activated by kaolin versus a panel of specific reagents. *Anesthesiology* 2011; 115: 294-302.
17. Gravholt CH, Mortensen KH, Andersen NH, Ibsen L, Ingerslev J, Hjerrild BE. Coagulation and fibrinolytic disturbances are related to carotid intima thickness and arterial blood pressure in Turner syndrome. *Clinical Endocrinol* 2012; 76: 649-56.
18. Ingerslev J, Sørensen B. Parallel use of by-passing agents in hamophilia with inhibitors: a critical review. *Br J Haematol* 2011; 155: 256-62.

2012:

19. Sørensen B, Ingerslev J. Dynamic APTT parameters: applications in thrombophilia. *J Thromb Haemost* 2012; 10: 244-50.
20. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Grangrande P, Peerlink K, Celkan T, Özdemir KM, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Donniccar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal F; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. *J Thromb Haemost* 2012; 10: 615-22.
21. Mariani G, Dolce A, Napolitano M, Ingerslev J, Giansily-Blaizot M, Di Minno MD, Auerswald G, De Saez AR, Taglifieri A, Batarova A; STER (Seven Treatment Evaluation Registry). Invasive procedures and minor surgery in factor VII deficiency. *Haemophilia* 2012; 18: e63-5.
22. Astermark J, Makris M, Mauser-Bunschoten E, Nemes L, D'orion R, Oldenburg J, Ingerslev J. Malignancy in Haemophilia Workshop Group. *Haemophilia* 2012; 18: 664-71.
23. Arildsen H, Sørensen KE, Ingerslev J, Østergaard LJ, Laursen AL. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. *HIV Med* 2013; 14: 1-9.
24. Larsen OH, Fenger-Eriksen C, Ingerslev J, Sørensen B. mImproved point-of-care identification of hyperfibrinolysis is needed. *Thromb Res* 2012; 130: 690-1.
25. Peyvandi F, DiMichele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; Project Concensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost* 2012; 10: 1938-43.
26. Powell J, Martinowitz U, Windyga J, DiMinno G, Hellmann A, Pabinger I, Maas Enriques M, Schwartz L, Ingerslev J; LipLong Study Investigators. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomized, active-controlled, double-blind study. *Thromb Haemost* 2012; 108: 913-22.

2013:

27. Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. *Br J Haematol* 2013; 160: 228-36.
28. Saulyte Trakymiene S, Clausen N, Poulsen LH, Ingerslev J, Rageliene L. Progression of haemophilic arthropathy in children: a Lithuanian-Danish comparative study. *Haemophilia* 2013; 19: 212-8.
29. Mariani G, Napolitano M, Dolce A, Perez Garrido R, Batorova A, Karimi M, Platokouki H, Auerswald G, Bertrand AM, Di Minno G, Schved JF, Bjerre J, Ingerslev J, Sørensen B, Ruiz-Saez A; Seven Treatment Evaluation Registry; International Factor VII Deficiency Study Group. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. *Thromb Haemost* 2013; 109: 238-47.
30. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Battle J, Cancaiani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. *Blood* 2013; 121: 2336-9.
31. Jensen MS, Larsen OH, Christiansen K, Fenger-Eriksen C, Ingerslev J, Sørensen B. Platelet activation and aggregation: the importance of thrombin activity – a laboratory model. *Haemophilia* 2013; 19: 403-8.
32. Napolitano M, Giansily-Blaizot M, Dolce A, Schved JF, Auerswald G, Ingerslev J, Bjerre J, Altisent C, Charoenkwan P, Michaels L, Chuansumrit A, Di Minno G, Caliskan U, Mariani G. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). *Haematologica* 2013; 4: 538-44.
33. Hampshire D, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T, Ingerslev J, Peake IR, Goodeve AC. Identification and characterization of mutations associated with von Willebrand disease in a Turkish patient cohort. *Thromb Haemost* 2013; 110: 264-74.
34. Palsson R, Vidarsson B, Gudmundsdottir BR, Larsen OH, Ingerslev J, Sørensen B, Onundarson PT. Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries. *Platelets* 2013; Aug 2013.

2014:

Ingerslev J, Lethagen S, Hvitfeldt Poulsen L, Sørensen B, Lopatina E, Tentsova I, Yastrubinskaya O, Pluyshch OP. Long-standing prophylactic therapy vs. Episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients. *Haemophilia* 2014; 20: 58-64.

Batorova A, Mariani G, Kavakli K, de Saez AR, Caliskan U, Karimi M, Pinotti M, Napolitano M, Dolce A, Sørensen B, Ingerslev J; STER Study Group. Inhibitors to factor VII in congenital factor VII deficiency. *Haemophilia* 2014; 20: 188-91.

## **Disclosures**

Member of advisory boards as well as served paid consultancies for pharmaceutical industries, including Novo Nordisk, Baxter, Bayer, BiogenIdec, CLS Behring, and Bio Products Limited, and also on several occasions received fees as a speaker or teacher on their behalf.

### Organisational roles at Congresses

1990 Member of Scientific Committees, organizer of international meetings, member of abstract reviewing committees, and chairmanship on numerous occasions since 1990.

### University of Aarhus

1989–1993 Elect member, the Faculty of Health Sciences, University of Aarhus

### Other Universities

2009-2013 Appointed Visiting Professor at King's College Medical School, London

### International Scientific Organisations

1992- Appointed member of the Scientific and Standardization Subcommittee on von Willebrand factor, The International Society of Thrombosis and Haemostasis

1995-1997 Co-chairman, Scientific and Standardization Committee for factor VIII & IX The International Society on Thrombosis and Haemostasis

1997-2000 Chairman, The Scientific and Standardization Subcommittee on factor VIII/IX, The International Society on Thrombosis and Haemostasis, 1997 -2000

2003- Senior Advisory Board member, The Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, 2003 –

- 2007- Elected Secretary, European Association for Haemophilia and Allied Disorders, established June 2007
- 2008-2009 Member of the Scientific Advisory Board of the European Haematology Association Congresses